You are viewing the site in preview mode

Skip to main content
Fig. 2 | BMC Urology

Fig. 2

From: Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations

Fig. 2

Kaplan Meier curve estimating OS for 55 patients from the next line of systemic therapy for kidney cancer after discontinuation of IO-VEGF. Median OS was 24.5 months (95% CI, 12.0– NE) and 12-month OS probability was 63.3% (95% CI, 48.6–74.9). Median follow up time for survivors was 18 months (range: 0, 44). OS (Overal Survival), IO-VEGF (Immune-Oncology and Vascular Endothelial Growth Factor targeted therapy)

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us